The Role of Metastasis-Directed Radiotherapy in Oligometastatic Bladder and Upper Tract Cancer

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Comron Hassanzadeh, MD, of MD Anderson Cancer Center, gave an overview of his research on metastasis-directed therapy for urothelial carcinoma in the bladder and upper tract.

He elaborates on the benefits of MDT for patients with progressive or de novo disease, nothing that his research showed a PFS of 19 months and OS of over 40 months, as well as a very low rate of treatment-related adverse events.